Roche

News

Roche begins phase 3 trial of Actemra in COVID-19 pneumonia

Roche is to begin a phase 3 trial of its Actemra/RoActemra as a treatment for patients hospitalised with severe COVID-19 pneumonia, following independent research in China suggesting it may

News

Coronavirus to disrupt EU pharma drug launches, analysts war...

Big European launches of drugs for cancer, HIV, and sickle cell disease could be affected by coronavirus, according to a new analysis from Jefferies.

News

Janssen J&J Johnson and Johnson pharmaceutical companies

Janssen antibody could be lung cancer breakthrough

The FDA thinks a dual-target antibody from Janssen could set new standards in treatment for certain patients with lung cancer, whose disease has progressed after chemotherapy and are unlike

News

China backs Roche's Actemra to fight coronavirus complicatio...

Chinese authorities have issued guidelines recommending Roche’s anti-inflammation drug Actemra to combat severe complications caused by the COVID-19 coronavirus.

News

AbbVie/Roche's Venclexta fails in confirmatory AML trial

AbbVie and Roche's Venclexta has failed to significantly improve overall survival in an acute myeloid leukaemia (AML) trial that was supposed to confirm its efficacy.

News

NICE rejects Roche's Polivy combination in advanced lymphoma

England’s NHS should not fund Roche’s Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine for adults with a form of advanced lymphoma, NICE has said in first draft g

Roche begins phase 3 trial of Actemra in COVID-19 pneumonia

Coronavirus to disrupt EU pharma drug launches, analysts war...

Janssen antibody could be lung cancer breakthrough

China backs Roche's Actemra to fight coronavirus complicatio...

AbbVie/Roche's Venclexta fails in confirmatory AML trial

NICE rejects Roche's Polivy combination in advanced lymphoma

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks